Диссертация (1139581), страница 49
Текст из файла (страница 49)
Refining papillary balloon dilation: Less is better!New Delhi, India. - J. Gastroenterol. Hepatol. 2008; 23: 867-871.303. Prat F., Amaris J., Ducot B. et al. Nifedipine for prevention of post-ERCPpancreatitis: a prospective, double-blind randomized study. Gastrointest Endosc2002; 56: 202-208.304.
Qiu P., Cui X., Barochia A., Li Y., Natanson C., Eichacker P. Q. Theevolving experience with therapeutic TNF inhibition in sepsis: considering thepotential influence of risk of death. Expert Opinion on Investigational Drugs 2011;20(11): 1555-1564.305. Rabenstein T., Fischer B., Wiessner V. et al. Low-molecular-weight heparindoes not prevent acute post-ERCP pancreatitis.
Gastrointest Endosc 2004; 59: 606613.306. Ranieri V.M., Thompson B.T., Barie P.S. et al. Drotrecogin alfa (activated)in adults with septic shock. The New England Journal of Medicine 2012; 366:2055-2064.307. Ranson J.H., Rifkind K.M., Roses D.F. et al. Prognostic signs and the role ofoperative management in acute pancreatitis. Surg Gynecol Obstet. 1974; 139: 6981.308. Raraty M.G.T., Halloran C.M., Dodd S.
et al. Minimal access retroperitonealpancreatic necrosectomy: improvement in morbidity and mortality with a lessinvasive approach. Annals of Surgery 2010; 251(5): 787-793.309. Raty S., Sand J., Pulkkinen M., Matikainen M., Nordback I. Post-ERCPpancreatitis: reduction by routine antibiotics. J Gastrointest Surg 2001; 5: 339-345.310. Rodriguez J.R., Razo A.O., Targarona J., Thayer S.P., Rattner D.W.,Warshaw A.L. et al. Debridement and closed packing for sterile or infectednecrotizing pancreatitis: insights into indications and outcomes in 167 patients.Ann Surg 2008; 247: 294-299.311.
Sakorafas G.H., Lappas C., Mastoraki A., Delis S.G., Safioleas M. Currenttrends in the management of infected necrotizing pancreatitis. Infect Disord DrugTargets 2010; 10: 9-14.307312. Sakorafas G.H., Lappas C., Mastoraki A., Delis S.G., Safioleas M. Currenttrends in the management of infected necrotizing pancreatitis. Infect Disord DrugTargets 2010; 10: 9-14.313. Salminen P., Laine S., Gullichsen R. Severe and fatal complications afterERCP: Analysis of 2555 procedures in a single experienced center.
Finland: SurgEndosc. – 2008; 22: 1965-1970.314. Sanjay P., Yeeting S., Whigham C., Judson H. Endoscopic sphincterotomyand interval cholecystectomy are reasonable alternatives to index cholecystectomyin severe acute gallstone pancreatitis (GSP).
Scotland, UK: Surg Endosc. 2008; 22:1832-1837.315. Sarles H. Proposal adopted unanimously by the participants of theSymposium, Marseille, 1963. Bibl. Gastroenterol 1965; 7; 7-8.316. Schiphorst A.H.W., Besselink M.G.H. et al. Timing of cholecystectomyafter endoscopic sphincterotomy for common bile duct stones. The Netherlands:Surg Endosc. 2008; 22: 2046-2050.317. Schneider L., Büchler M.W., Werner J.
Acute pancreatitiswith an emphasison infection. Infect Dis Clin North Am 2010; 24: 921-941.318. Schutte K., Malfertheiner P. Markers for predicting severity and progressionof acute pancreatitis. Best Practice and Research in Clinical Gastroenterology2008; 22(1): 75-90.319. Schwartz J.J., Lew R.J., Ahmad N.A. et al. The effect of lidocaine sprayedon the major duodenal papilla on the frequency of post-ERCP pancreatitis.Gastrointest Endosc 2004; 59: 179-184.320. Shao L.M., Chen Q.Y., Chen M.Y., Cai J.T. Nitroglycerin in the preventionof post-ERCP pancreatitis: a meta-analysis.
Dig Dis Sci 2010; 55: 1-7.321. Sherman S., Cheng C.L., Costamagna G. et al. Interleukin-10 ERCP StudyGroup. Efficacy of recombinant human interleukin-10 in prevention of postendoscopic retrograde cholangiopancreatography pancreatitis in subjects withincreased risk. Pancreas. 2009; 38: 267-274.308322. Sherman S., Hawes R.H., Troiano F.P., Lehman G.A. Pancreatitis followingbile duct sphincter of Oddi manometry: utility of the aspirating catheter.Gastrointest Endosc 1992; 38: 347-350.323.
Singh P., Das A., Isenberg G. et al. Does prophylactic pancreatic stentplacement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis ofcontrolled trials. Gastrointest Endosc 2004; 60: 544-550.324. Skjesol A., Skjaeveland I., Elnaes M., Timmerhaus G., Fredriksen B.N., etal.
IPNV with high and low virulence: host immune responses and viral mutationsduring infection. Virol J 2011; 8: 396.325. Sternlieb J.M., Aronchick C.A., Retig J.N. et al. A multicenter, randomized,controlled trial to evaluate the effect of prophylactic octreotide on ERCP-inducedpancreatitis. Am J Gastroenterol 1992; 87: 1561-1566.326. Tenner S., Baillie J., Dewitt J., Vege S.S. American college ofgastroenterology guideline: management of acute pancreatitis.
The AmericanJournal of Gastroenterology 2013; 108(9): 1400-1415.327. Testoni P.A., Bagnolo F. Pain at 24 hours associated with amylase levelsgreater than 5 times the upper normal limit as the most reliable indicator of postERCP pancreatitis. Gastrointest Endosc 2001; 53: 33-39.328. Testoni P.A., Bagnolo F., Andriulli A. et al. Octreotide 24-h prophylaxis inpatients at high risk for post-ERCP pancreatitis: results of a multicenter,randomized, controlled trial.
Aliment Pharmacol Ther 2001; 15: 965-972.329. The Society for Surgery of the Alimentary Tract Patient Care Committee.Treatment of acute pancreatitis. J. Gastrointest. Surg. 1998; 2: 487-488.330. Thomas P.R., Sengupta S. Prediction of pancreatitis following endoscopicretrograde cholangiopancreatography by the 4-h post procedure amylase level.
JGastroenterol Hepatol 2001; 16: 923-926.331. Thomopoulos K.C., Pagoni N.A., Vagenas K.A. et al. Twenty four hourprophylaxis with increased dosage of octreotide reduces the incidence of postERCP pancreatitis. Gastrointest Endosc 2006; 64: 726-731.309332. Toouli J., Brooke-Smith M., Bassi C., Carr-Locke D., Telford J., Freeny P.,Imrie C., Tandon R. Guidelines for the management of acute pancreatitis. JGastroenterol Hepatol 2002; 17 Suppl: 515-539.333.
Tsujino T., Komatsu Y., Isayama H. et al. Ulinastatin for pancreatitis afterendoscopic retrograde cholangiopancreatography: a randomized, controlled trial.Clin Gastroenterol Hepatol 2005; 3: 376-383.334. Ueki T., Otani K., Kawamoto K. et al. Comparison between ulinastatin andgabexatemesylateforthepreventionofpost-endoscopicretrogradecholangiopancreatography pancreatitis: a prospective, randomized trial. JGastroenterol 2007; 42: 161-167.335. Uomo G. Lesson from acute experimental pancreatitis: multidrug strategiesis effective than single-target therapy.
Journal of the Pancreas 2012; 13(5): 543544.336. Van Baal M.C., van Santvoort H.C., Bollen T.L., Bakker O.J., BesselinkM.G., Gooszen H.G. Systematic review of percutaneous catheter drainage asprimary treatment for necrotizing pancreatitis. Br J Surg 2011; 98: 18-27.337. Van Santvoort H.C., Besselink M.G., Bakker O.J. et al. A step-up approachor open necrosectomy for necrotizing pancreatitis.
The New England Journal ofMedicine 2010; 362(16): 1491-1502.338. Vandervoort J., Soetikno R.M., Tham T.C.K. et al. Risk factors forcomplications after performance of ERCP. Gastrointest Endosc 2002; 56: 652–656.339. Verma D., Kapadia A., Adler D.G. Pure versus mixed electrosurgical currentfor endoscopic biliary sphincterotomy: a meta-analysis of adverse outcomes.Gastrointest Endosc 2007; 66: 283-290.340. Wang P., Li Z.S., Liu F. et al.
Risk factors for ERCP-related complications:a prospective multicenter study. Am J Gastroenterol 2009; 104: 31-40.341. Wehrmann T., Stergiou N., Schmitt T., Dietrich C.F., Seifert H. Reducedrisk for pancreatitis after endoscopic microtransducer manometry of the sphincterof Oddi: a randomized comparison with the perfusion manometry technique.Endoscopy 2003; 35: 472-477.310342.
Weinberg B.M., Shindy W., Lo S. Endoscopic balloon sphincter dilation(sphincteroplasty) versus sphincterotomy for common bile duct stones. CochraneDatabase Syst Rev 2006; CD004890.343. Werner J., Hartwig W., Hackert T. et al. Multidrug strategies are effective inthe treatment of severe experimental pancreatitis. Surgery 2012; 151(3): 372-381.344. Williams E.J., Taylor S., Fairclough P. et al. Risk factors for complicationfollowing ERCP; results of a large-scale, prospective multicenter study. Endoscopy2007; 39: 793-801.345. Woeste G., Wullstein C., Meyer S., Usadel K.H., Hopt U.T., et al.Octreotide attenuates impaired microcirculation in postischemic pancreatitis whenadministered before induction of ischemia. Transplantation 2008; 86: 961-967.346. Wright S.E., Lochan R., Imrie K., Baker C., Nesbitt I.D., Kilner A.J. et al.Quality of life and functional outcome at 3, 6 and 12 months after acute necrotisingpancreatitis.
Intensive Care Med 2009; 35: 1974-1978.347. Wysocki A.P., McKay C.J., Carter C.R. Infected pancreatic necrosis:minimizing the cut. ANZ J Surg 2010; 80: 58-70.348. Xiong G.S., Wu S.M., Zhang X.W., Ge Z.Z. Clinical trial of gabexate in theprophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis.Braz J Med Biol Res 2006; 39: 85-90.349.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
